Loss of the KN Motif and AnKyrin Repeat Domain 1 (KANK1) Leads to Lymphoid Compartment Dysregulation in Murine Model
Authors:
- Marwa AlmosailleakhMAMarwa Almosailleakh
- Sofia BentivegnaSBSofia Bentivegna
- Samuele NarcisiSNSamuele Narcisi
- Sébasitien J. BenquetSBSébasitien J. Benquet
- Linn GillbergLGLinn Gillberg
- Carmen P. Montaño-AlmendrasCMCarmen P. Montaño-Almendras
- Simonas SavickasSSSimonas Savickas
- Erwin M. SchoofESErwin M. Schoof
- Amelie WegenerAWAmelie Wegener
- Hérve LucheHLHérve Luche
- Henrik E. JensenHJHenrik E. Jensen
- Christophe CômeCCChristophe Côme
Open Access
Abstract
The KN Motif and AnKyrin Repeat Domain 1 (KANK1) is proposed as a tumour suppressor gene, as its expression is reduced or absent in several types of tumour tissue, and over-expressing the protein inhibited the proliferation of tumour cells in solid cancer models. We report a novel germline loss of heterozygosity mutation encompassing the KANK1 gene in a young patient diagnosed with myelodysplastic neoplasm (MDS) with no additional disease-related genomic aberrations. To study the potential role of KANK1 in haematopoiesis, we generated a new transgenic mouse model with a confirmed loss of KANK1 expression. KANK1 knockout mice did not develop any haematological abnormalities; however, the loss of its expression led to alteration in the colony forming and proliferative potential of bone marrow (BM) cells and a decrease in hematopoietic stem and progenitor cells (HSPCs) population frequency. A comprehensive marker expression analysis of lineage cell populations indicated a role for Kank1 in lymphoid cell development, and total protein analysis suggests the involvement of Kank1 in BM cells’ cytoskeleton formation and mobility.Keywords
Funding Information
- Novo Nordisk Fonden (NNF17CC0027852, R302-A17259, R223-A13071)
- Greater Copenhagen Health Science Partners (NNF17CC0027852, R302-A17259, R223-A13071)
- Kræftens Bekæmpelse (NNF17CC0027852, R302-A17259, R223-A13071)
This publication has 34 references indexed in Scilit:
- Genome engineering using the CRISPR-Cas9 systemNature Protocols, 2013
- RhoA GTPase controls cytokinesis and programmed necrosis of hematopoietic progenitorsJournal of Experimental Medicine, 2013
- Parallel Reaction Monitoring for High Resolution and High Mass Accuracy Quantitative, Targeted ProteomicsMolecular & Cellular Proteomics, 2012
- KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemiaLeukemia, 2010
- Skyline: an open source document editor for creating and analyzing targeted proteomics experimentsBioinformatics, 2010
- Immune pathology associated with altered actin cytoskeleton regulationAutoimmunity, 2009
- Kank regulates RhoA-dependent formation of actin stress fibers and cell migration via 14-3-3 in PI3K–Akt signalingJournal of Cell Biology, 2008
- Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTipsNature Protocols, 2007
- Regulation of T-cell activation by the cytoskeletonNature Reviews Immunology, 2007
- Deletion of the ANKRD15 gene at 9p24.3 causes parent-of-origin-dependent inheritance of familial cerebral palsyHuman Molecular Genetics, 2005